China's NMPA approves Argenx's and Zai Lab's BLA for muscle-weakening disease treatment
June 30 (Reuters) - China's National Medical Products
Administration (NMPA) has approved Zai Lab Limited's 9688.HK
and Argenx SE's ARGX.BR Biologics License Application (BLA)
for VYVGART, a treatment for generalised myasthenia gravis
(gMG), muscle-weakening disease, in anti-body positive adults,
the Dutch company said on Friday.
Zai Lab will work with the National Healthcare Security
Administration (NHSA) for National Reimbursement Drug List
(NRDL) inclusion to enable broad access for patients, Argenx
said in a statement.
(Reporting by Dina Kartit, Editing by Louise Heavens)
((Dina.Kartit@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows